Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity

Overview of attention for article published in JAMA Oncology, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 13 news outlets
twitter: 46 X users

facebook: 1 Facebook page

Readers on

mendeley: 108 Mendeley

Summary News X Facebook

So far, Altmetric has seen 63 X posts from 46 X users, with an upper bound of 296,598 followers.

RT @BCOSCardioOnc: Food for thought. Are the historical anthracycline conversion ratios still appropriate for use in contemporary clinical…

05 Feb 2024

Reply Repost Favourite

Food for thought. Are the historical anthracycline conversion ratios still appropriate for use in contemporary clinical practice and research? https://t.co/rjqFDLTKQR

05 Feb 2024

Reply Repost Favourite

Reconsideration of #Anthracyclin #Doxorubicin #EquivalenceRatios for Late-Onset Cardiotoxicity. #Mitoxantrone 2.6x more cardiotoxic than conventional belief (4:1 Doxo conversion) https://t.co/zEY6I0GNlv via @JAMAOnc part of @JAMANetwork #LateEffects #AML

01 Mar 2021

Reply Repost Favourite

https://t.co/ryUbN3fixQ

31 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 59 additional X posts.